An Update on the Use of Pap Tests and Human Papillomavirus Testing
|
Shikha Bose, MD
Director, Cytopathology Laboratory, Cedars Sinai Medical Center, Los Angeles, CA
Associate Clinical Professor, School of Medicine, UCLA, Los Angeles, CA
|
|
Upon completion of this program, you will be able to:
- Explain the biology of the human papillomavirus (HPV) and its association with cervical cancer
- Describe the advantages and limitations of the existing modes of cervical cancer screening (Pap and HPV tests)
- Delineate the newer modes of HPV testing
|
Although the Pap test has been the most effective cancer screening tool known to date and has resulted in a reduction in the incidence of cervical cancer by 80%, the field of cervical cancer screening is changing at a rapid pace. Introduction of the liquid-based collection medium, incorporation of testing for the human papillomavirus (HPV), FDA approval of the HPV vaccine, and new modalities of testing on the horizon–tests for E6/E7 mRNA, p16, and Pro ExC -- are landmark changes occurring as the field evolves. To fully understand and implement these changes, a basic understanding of the biology of HPV infection, its association with low-grade and high-grade lesions of the cervix, and the progression to cervical cancer is imperative.
This presentation will address:
- The current status of Pap/HPV testing for cervical cancer screening
- The advantages and disadvantages of the different testing modalities
- The basis of the developing new tests in the setting of HPV biology.
Intended Audience: Practicing Pathologists, Residents, Laboratory Managers, Bench Supervisors, Cytotechnologists
The ASCP designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation n the activities.
ASCP designates this activity for a maximum of 1 CMLE credits. This activity meets CMP and state licensure requirements for laboratory personnel.